Milton H Harris

US Patent:

6638500, Oct 28, 2003

Filed:

Oct 30, 2000

Appl. No.:

09/698133

Inventors:

Nabil El-Tayar - Milton MA
Michael J. Roberts - Madison AL
Milton Harris - Huntsville AL
Wayne Sawlivich - Wilmington MA

Assignee:

Applied Research Systems ARS Holding N.V. - Curacao

International Classification:

A61K 3821

US Classification:

424 856, 424 7831, 530351, 530402, 514 12

Abstract:

PEG-IFN- conjugates, where a PEG moiety is covalently bound to Cys of human IFN-, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-.

US Patent:

7700314, Apr 20, 2010

Filed:

Feb 13, 2007

Appl. No.:

11/674476

Inventors:

Nabil El-Tayar - Milton MA, US
Michael J. Roberts - Madison AL, US
Milton Harris - Huntsville AL, US
Wayne Sawlivich - Wilmington MA, US

Assignee:

Merck Serono SA - Coinsins, Vaud

International Classification:

C12P 21/00
C08G 65/08
C07K 14/52

US Classification:

435 681, 525 59, 525 61, 530351

Abstract:

PEG-IFN-β conjugates, where a PEG moiety is covalently bound to Cysof human IFN-β, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-β.

US Patent:

20040043002, Mar 4, 2004

Filed:

Aug 28, 2003

Appl. No.:

10/649609

Inventors:

Nabil El-Tayar - Milton MA, US
Michael Roberts - Madison AL, US
Milton Harris - Huntsville AL, US
Wayne Sawlivich - Wilmington MA, US

Assignee:

APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. - Curacao

International Classification:

A61K038/21
C07K014/54

US Classification:

424/085600, 530/351000

Abstract:

PEG-IFN- conjugates, where a PEG moiety is covalently bound to Cysof human IFN-, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-.

US Patent:

61800074, Jan 30, 2001

Filed:

Jan 31, 1998

Appl. No.:

9/016518

Inventors:

Frank Gentile - Warwich RI
Molly Shoichet - Canton CA
Milton Harris - Huntsville AL

Assignee:

Neurotech, SA - Evry

International Classification:

C08L 2044
C08L 8102
C12N 1104
C12N 1108

US Classification:

21050023

Abstract:

A permselective graft polymer is disclosed that is formed by converting into intermediate reactive sites a portion of the cyano groups of a backbone polymer containing --CH. sub. 2 --CH(--C. tbd. N)-- units, and grafting polyalkylene oxide polymer chains to the backbone polymer through the reactive sites. Either the backbone polymer of a polymer resin or a permselective polymer membrane can be grafted. When a resin is used, it is formed into a permselective polymer membrane using known methods. The resulting permselective membrane can be formed into hollow fibers or flat sheets for the encapsulation of living cells. The encapsulated cells are then implanted into a patient in need of the biologically active factors produced by the cells. The permselective graft polymer membrane exhibits good molecular diffusion with minimal protein adsorption.